EQRx (EQRX) Long-Term Debt : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is EQRx Long-Term Debt?

EQRx's Long-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.

EQRx Long-Term Debt Historical Data

The historical data trend for EQRx's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQRx Long-Term Debt Chart

EQRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Long-Term Debt

EQRx Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Long-Term Debt	Get a 7-Day Free Trial								-	-	-	-	-

EQRx (NAS:EQRX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

EQRx Long-Term Debt Related Terms

Thank you for viewing the detailed overview of EQRx's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

EQRx (EQRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EQRx Inc (NAS:EQRX) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Hampshire Street, Cambridge, MA, USA, 02139

Website

https://www.eqrx.com

EQRx Inc is a biotechnology company. the company has more than 10 programs in its pipeline, including clinical, preclinical and drug engineering targets for the treatment of oncology and immune-inflammatory conditions. The program includes Aumolertinib, Lerociclib, Sugemalimab, Nofazinlimab, and others.

Executives

Dina Ciarimboli	officer: General Counsel and Secretary	EQRX, INC., 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Clive Meanwell	director	THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Andreessen Horowitz Lsv Fund I-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Bio Fund Ii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Bio Ii, L.l.c.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Ah Equity Partners Lsv Ii, L.l.c.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-q, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Andreessen Horowitz Lsv Fund Ii-b, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Krishna Yeshwant	director	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Kathryn E Giusti	director	1499 POST ROAD, FAIRFIELD CT 06824
Melanie Nallicheri	director, officer: Chief Executive Officer	C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Ah Bio Fund Iii, L.p.	10 percent owner	2865 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025